僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Camrelizumab （SHR-1210） is a potent humanied high-affinity IgG4-κ monoclonal antibody （mAb） to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,